

Moses S Elisaf

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7422519/moses-s-elisaf-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

357
papers

11,539
citations

54
h-index

89
g-index

388
ext. papers

12,974
ext. citations

3.8
avg, IF

6.52
L-index

#	Paper	IF	Citations
357	Recommendations for lipid modification in patients with ischemic stroke or transient ischemic attack: A clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society. <i>International Journal of Stroke</i> , 2021 , 16, 738-750	6.3	2
356	Lipoprotein(a): A Concealed Precursor of Increased Cardiovascular Risk? A Real-World Regional Lipid Clinic Experience. <i>Archives of Medical Research</i> , 2021 , 52, 397-404	6.6	2
355	Metabolically healthy obesity and risk of incident type 2 diabetes in 1077 statin-treated individuals: A six-year retrospective study. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 2341-2344	3.9	3
354	Cardioprotective Properties of HDL: Structural and Functional Considerations. <i>Current Medicinal Chemistry</i> , 2020 , 27, 2964-2978	4.3	15
353	Arterial Stiffness, Cognitive Dysfunction and Adherence to Antihypertensive Agents. Is there a Link to Hypertensive Patients?. <i>Current Vascular Pharmacology</i> , 2020 , 18, 410-417	3.3	3
352	Drug-Induced Hypophosphatemia: Current Insights. <i>Drug Safety</i> , 2020 , 43, 197-210	5.1	13
351	PCSK9 inhibitors in clinical practice: Novel directions and new experiences. <i>Hellenic Journal of Cardiology</i> , 2020 , 61, 241-245	2.1	7
350	Adherence to the National Guidelines for Follow-Up Protocol in Subjects with Type 2 Diabetes Mellitus in Greece: The GLANCE Study. <i>Diabetes Therapy</i> , 2020 , 11, 2887-2908	3.6	0
349	Early Signs of Atherogenic Features in the HDL Lipidomes of Normolipidemic Patients Newly Diagnosed with Type 2 Diabetes. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
348	Vitamin D status and cardiometabolic risk factors in Greek adolescents with obesity - the effect of vitamin D supplementation: a pilot study. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2020 , 5, e64-e71	0.9	5
347	Real-World Adequacy of Glycaemic Control in Treatment-Naïve Greek Patients with Type 2 Diabetes Mellitus Initiating Treatment with Metformin Monotherapy at the Maximum Tolerated Dose: The Reload Study. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2020 , 128, 224-230	2.3	1
346	No effect of fenugreek, bergamot and olive leaf extract on glucose homeostasis in patients with prediabetes: a randomized double-blind placebo-controlled study. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2019 , 4, e162-e166	0.9	2
345	Significant Weight Loss in a Patient Taking Olmesartan: An Unusual Case Report. <i>Current Drug Safety</i> , 2019 , 14, 238-241	1.4	0
344	Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes. <i>Clinical Pharmacology: Advances and Applications</i> , 2019 , 11, 133-143	1.5	6
343	High-Density Lipoprotein Cholesterol and Hyponatremia: An Unsolved Gordian Knot. <i>American Journal of Medicine</i> , 2019 , 132, e47-e48	2.4	1
342	Reduced Serum Vitamin D Levels Are Associated with Insulin Resistance in Patients with Obstructive Sleep Apnea Syndrome. <i>Medicina (Lithuania)</i> , 2019 , 55,	3.1	5
341	Influence of Supervised Disease Understanding and Diabetes Self-Management on Adherence to Oral Glucose-Lowering Treatment in Patients with Type 2 Diabetes. <i>Diabetes Therapy</i> , 2019 , 10, 1407-1422	3.6	3

340	Attainment of cholesterol target values in Greece: results from the Dyslipidemia International Study II. <i>Archives of Medical Science</i> , 2019 , 15, 821-831	2.9	4
339	Hyponatremia-Inducing Drugs. <i>Frontiers of Hormone Research</i> , 2019 , 52, 167-177	3.5	12
338	Atherogenic dyslipidemia increases the risk of incident diabetes in statin-treated patients with impaired fasting glucose or obesity. <i>Journal of Cardiology</i> , 2019 , 74, 290-295	3	13
337	Emerging Fixed-Dose Combination Treatments for Hyperlipidemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019 , 24, 315-322	2.6	11
336	The impact of temporal artery biopsy for the diagnosis of giant cell arteritis in clinical practice in a tertiary university hospital. <i>PLoS ONE</i> , 2019 , 14, e0210845	3.7	4
335	Effects of Angiotensin-Like 3 on Triglyceride Regulation, Glucose Homeostasis, and Diabetes. <i>Disease Markers</i> , 2019 , 2019, 6578327	3.2	21
334	Hyponatremia in Acute Stroke Patients: Pathophysiology, Clinical Significance, and Management Options. <i>European Neurology</i> , 2019 , 82, 32-40	2.1	12
333	Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects. <i>Current Vascular Pharmacology</i> , 2019 , 17, 332-340	3.3	5
332	SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. <i>Postgraduate Medicine</i> , 2019 , 131, 82-88	3.7	44
331	Apolipoprotein CIII and diabetes. Is there a link?. <i>Diabetes/Metabolism Research and Reviews</i> , 2019 , 35, e3118	7.5	8
330	Bridging the treatment gap in patients at Extreme Cardiovascular risk: Evidence from a lipid clinic. <i>Atherosclerosis</i> , 2019 , 281, 216-218	3.1	0
329	Effect of combined vitamin D administration plus dietary intervention on oxidative stress markers in patients with metabolic syndrome: A pilot randomized study. <i>Clinical Nutrition ESPEN</i> , 2019 , 29, 198-202	1.3	6
328	Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment. <i>Journal of Hypertension</i> , 2018 , 36, 1427-1440	1.9	48
327	Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directions. <i>Journal of Hypertension</i> , 2018 , 36, 1441-1455	1.9	26
326	Hypolipidemic Drugs and Diabetes Mellitus-Mechanisms and Data From Genetic Trials. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018 , 23, 187-191	2.6	2
325	Uric acid and cardiovascular risk: What genes can say. <i>International Journal of Clinical Practice</i> , 2018 , 72, e13048	2.9	12
324	SGLT2 inhibitors: are they safe?. <i>Postgraduate Medicine</i> , 2018 , 130, 72-82	3.7	36
323	Effects of incretin-based therapies on renal function. <i>European Journal of Pharmacology</i> , 2018 , 818, 103-109	3.9	10

322	Uric acid and incident chronic kidney disease in dyslipidemic individuals. <i>Current Medical Research and Opinion</i> , 2018 , 34, 1193-1199	2.5	11
321	Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018 , 23, 3-12	2.6	20
320	Pharmacological management of hyponatremia. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1337-1344	4	4
319	Use of guideline-recommended management in established coronary heart disease in the observational DYSIS II study. <i>International Journal of Cardiology</i> , 2018 , 270, 21-27	3.2	11
318	SGLT2 inhibitors and the kidney: Effects and mechanisms. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2018 , 12, 1117-1123	8.9	26
317	Treatment of Hypertension in Chronic Kidney Disease. <i>Current Hypertension Reports</i> , 2018 , 20, 64	4.7	16
316	Body mass index impacts the choice of lipid-lowering treatment with no correlation to blood cholesterol - Findings from 52 916 patients in the Dyslipidemia International Study (DYSIS). <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2670-2674	6.7	7
315	Incretins and Lipid Metabolism. <i>Current Medicinal Chemistry</i> , 2018 , 25, 2133-2139	4.3	9
314	Prevalence, Identification, and Scouting for Familial Hypercholesterolaemia Including Registries. <i>Current Pharmaceutical Design</i> , 2018 , 24, 3605-3615	3.3	4
313	Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 117-125	5.5	4
312	Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?. <i>Current Opinion in Lipidology</i> , 2018 , 29, 333-339	4.4	15
311	Arterial damage and cognitive impairment in patients with chronic kidney disease. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 1643	2.3	1
310	Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). <i>Atherosclerosis</i> , 2018 , 277, 308-313	3.1	15
309	SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 1113-1121	5.5	17
308	Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe. <i>European Journal of Preventive Cardiology</i> , 2018 , 25, 1966-1976	3.9	30
307	SGLT1 inhibition: Pros and cons. <i>European Journal of Pharmacology</i> , 2018 , 838, 153-156	5.3	19
306	Diagnostic lipid changes in patients with visceral leishmaniasis. <i>Hospital Practice (1995)</i> , 2018 , 46, 229-232	2	2
305	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. <i>Metabolism: Clinical and Experimental</i> , 2017 , 71, 17-32	12.7	152

304	Does Supplementation with Omega-3 PUFAs Add to the Prevention of Cardiovascular Disease?. <i>Current Cardiology Reports</i> , 2017 , 19, 47	4.2	20
303	Lipid testing in infectious diseases: possible role in diagnosis and prognosis. <i>Infection</i> , 2017 , 45, 575-588	5.8	28
302	Sitosterolemia: A multifaceted metabolic disorder with important clinical consequences. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 1095-1100	4.9	15
301	Phosphate imbalance in patients with heart failure. <i>Heart Failure Reviews</i> , 2017 , 22, 349-356	5	12
300	The CHADS and CHADS-VASc scores predict atrial fibrillation in dyslipidemic individuals: Role of incorporating low high-density lipoprotein cholesterol levels. <i>International Journal of Cardiology</i> , 2017 , 241, 194-199	3.2	13
299	Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis. <i>Diabetes and Metabolism</i> , 2017 , 43, 1-8	5.4	27
298	NMR-Based Lipid Profiling of High Density Lipoprotein Particles in Healthy Subjects with Low, Normal, and Elevated HDL-Cholesterol. <i>Journal of Proteome Research</i> , 2017 , 16, 1605-1616	5.6	15
297	Serum osmolal gap in clinical practice: usefulness and limitations. <i>Postgraduate Medicine</i> , 2017 , 129, 456-459	4.7	11
296	Statins and mortality: the untold story. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 938-941	3.8	2
295	Non-hemorrhage-related adverse effects of rivaroxaban. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2017 , 2, e108-e112	0.9	11
294	No effect of vitamin D supplementation on cardiovascular risk factors in subjects with metabolic syndrome: a pilot randomised study. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2017 , 2, e52-e60	0.9	15
293	Statin escape phenomenon: Fact or fiction?. <i>World Journal of Experimental Medicine</i> , 2017 , 7, 25-30	0.4	1
292	Uncontrolled Hypertension and Oncology: Clinical Tips. <i>Current Vascular Pharmacology</i> , 2017 , 16, 23-29	3.3	4
291	Pathophysiology of Diabetic Dyslipidaemia. <i>Current Vascular Pharmacology</i> , 2017 , 15, 566-575	3.3	14
290	Effects of increased body weight and short-term weight loss on serum PCSK9 levels - a prospective pilot study. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2017 , 2, e46-e51	0.9	9
289	Low high-density lipoprotein cholesterol levels improve the performance of the CHADS2 and CHA2DS2-VASc scores for the prediction of new-onset atrial fibrillation. <i>International Journal of Cardiology</i> , 2017 , 247, 18	3.2	1
288	Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 1121-1132	4.1	12
287	Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017 , 26, 2769-2777	2.8	4

286	Statin Therapy and Risk of Intracranial Hemorrhage in Patients with Ischemic Stroke. <i>Drug Safety</i> , 2017 , 40, 851-853	5.1	1
285	Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 399-408	5.5	15
284	Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?. <i>Diseases (Basel, Switzerland)</i> , 2017 , 5,	4.4	12
283	Hyponatremia in the elderly: challenges and solutions. <i>Clinical Interventions in Aging</i> , 2017 , 12, 1957-1965	4	49
282	Antidiabetic Drugs and the Kidney. <i>Current Pharmaceutical Design</i> , 2017 , 23, 6310-6320	3.3	6
281	Severe hyperkalemia following blood transfusions: Is there a link?. <i>World Journal of Nephrology</i> , 2017 , 6, 53-56	3.6	5
280	Effect of rosuvastatin or its combination with omega-3 fatty acids on circulating CD34(+) progenitor cells and on endothelial colony formation in patients with mixed dyslipidaemia. <i>Atherosclerosis</i> , 2016 , 251, 240-247	3.1	7
279	High triglyceride levels alter the correlation of apolipoprotein B with low- and non-high-density lipoprotein cholesterol mostly in individuals with diabetes or metabolic syndrome. <i>Atherosclerosis</i> , 2016 , 247, 58-63	3.1	16
278	Does this patient have hypertensive encephalopathy?. <i>Journal of the American Society of Hypertension</i> , 2016 , 10, 399-403		4
277	Evaluation and treatment of hypernatremia: a practical guide for physicians. <i>Postgraduate Medicine</i> , 2016 , 128, 299-306	3.7	13
276	The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 559-69	4.1	13
275	Electrolyte disorders associated with the use of anticancer drugs. <i>European Journal of Pharmacology</i> , 2016 , 777, 78-87	5.3	48
274	Omega-3 supplements and cardiovascular disease. Re: Sperling LS, Nelson JR. History and future of omega-3 fatty acids in cardiovascular disease. <i>Curr Med Res Opin</i> 2015; 32(2);301-311. <i>Current Medical Research and Opinion</i> , 2016 , 32, 583-4	2.5	1
273	Statin therapy with or without ezetimibe and the progression to diabetes. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 306-13	4.9	29
272	Effects of ezetimibe/simvastatin combination on metabolic parameters. <i>International Journal of Cardiology</i> , 2016 , 202, 273-4	3.2	7
271	Thiazide-associated hyponatremia in the elderly: what the clinician needs to know. <i>Journal of Geriatric Cardiology</i> , 2016 , 13, 175-82	1.7	25
270	The relationship between retinol-binding protein 4 and apolipoprotein B-containing lipoproteins is attenuated in patients with very high serum triglycerides: A pilot study. <i>Hormones</i> , 2016 , 15, 99-105	3.1	1
269	Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study. <i>Current Vascular Pharmacology</i> , 2016 , 14, 474-480	3.3	3

268	Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. <i>Hormones</i> , 2016 , 15, 8-14	3.1	21
267	The relationship between retinol-binding protein 4 and apolipoprotein B-containing lipoproteins is attenuated in patients with very high serum triglycerides: A pilot study. <i>Hormones</i> , 2016 , 15, 99-105	3.1	0
266	Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk. <i>European Journal of Internal Medicine</i> , 2016 , 34, 54-57	3.9	19
265	Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. <i>European Heart Journal Supplements</i> , 2016 , 18, C2-C12	1.5	56
264	A contemporary cross-sectional study on dyslipidemia management, cardiovascular risk status, and patients' quality of life in Greece: The CHALLENGE study. <i>International Journal of Cardiology</i> , 2016 , 217, 183-9	3.2	5
263	Pitavastatin and carbohydrate metabolism: what is the evidence?. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 955-60	3.8	7
262	Telmisartan: a multifaceted antihypertension drug. <i>Current Medical Research and Opinion</i> , 2016 , 32, 1397-8	3.8	1
261	The current role of thiazolidinediones in diabetes management. <i>Archives of Toxicology</i> , 2016 , 90, 1861-8	3.8	45
260	Ten pitfalls in the proper management of patients with hyponatremia. <i>Postgraduate Medicine</i> , 2016 , 128, 516-22	3.7	11
259	Cholesteryl ester transfer protein inhibitors: challenges and perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2016 , 14, 953-62	2.5	22
258	Safety considerations with fenofibrate/simvastatin combination. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 1481-93	4.1	18
257	Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic. <i>Angiology</i> , 2015 , 66, 346-53	2.1	20
256	Effects of benchmarking on the quality of type 2 diabetes care: results of the OPTIMISE (Optimal Type 2 Diabetes Management Including Benchmarking and Standard Treatment) study in Greece. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2015 , 6, 199-209	4.5	3
255	Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. <i>Diabetologia</i> , 2015 , 58, 1960-1	10.3	6
254	Correction of hypovolemia with crystalloid fluids: Individualizing infusion therapy. <i>Postgraduate Medicine</i> , 2015 , 127, 405-12	3.7	23
253	Statins and their increased risk of inducing diabetes. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 1835-44	4.1	20
252	Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. <i>Atherosclerosis</i> , 2015 , 243, 60-4	3.1	28
251	Statin use in prediabetic patients: rationale and results to date. <i>Therapeutic Advances in Chronic Disease</i> , 2015 , 6, 246-51	4.9	7

250	The effect of rosuvastatin on low-density lipoprotein subfractions in patients with impaired fasting glucose. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015 , 20, 276-83	2.6	7
249	Combining rosuvastatin with angiotensin-receptor blockers of different PPAR α -activating capacity: effects on high-density lipoprotein subfractions and associated enzymes. <i>Angiology</i> , 2015 , 66, 36-42	2.1	5
248	Ear lobe crease: a marker of coronary artery disease?. <i>Archives of Medical Science</i> , 2015 , 11, 1145-55	2.9	17
247	How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. <i>Current Medical Research and Opinion</i> , 2015 , 31, 221-8	2.5	16
246	Proprotein convertase subtilisin kexin 9 inhibitors: next generation in lipid-lowering therapy. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 287-98	5.4	6
245	Dapagliflozin in patients with type 2 diabetes mellitus. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2015 , 6, 29-41	4.5	18
244	Attainment of multifactorial treatment targets among the elderly in a lipid clinic. <i>Journal of Geriatric Cardiology</i> , 2015 , 12, 239-45	1.7	4
243	Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropirant on oxidative stress markers in patients with mixed dyslipidemia. <i>Cardiovascular Therapeutics</i> , 2014 , 32, 139-46	3.3	14
242	Emerging drugs for hyperlipidaemia: an update. <i>Expert Opinion on Emerging Drugs</i> , 2014 , 19, 471-88	3.7	5
241	Treatment of hyponatremia: the role of lixivaptan. <i>Expert Review of Clinical Pharmacology</i> , 2014 , 7, 431-43	5.8	12
240	Visceral leishmaniasis is associated with marked changes in serum lipid profile. <i>European Journal of Clinical Investigation</i> , 2014 , 44, 719-27	4.6	12
239	Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases. <i>Drug Safety</i> , 2014 , 37, 481-500	5.1	4
238	Diabetes mellitus and electrolyte disorders. <i>World Journal of Clinical Cases</i> , 2014 , 2, 488-96	1.6	144
237	Antihypertensive drugs and glucose metabolism. <i>World Journal of Cardiology</i> , 2014 , 6, 517-30	2.1	51
236	Nicotinic acid/laropirant reduces platelet count but increases mean platelet volume in patients with primary dyslipidemia. <i>Archives of Medical Science</i> , 2014 , 10, 439-44	2.9	6
235	Hypercalcemia and acute renal failure associated with calcium carbonate consumption in a patient with hypoparathyroidism. <i>Archives of Medical Science</i> , 2014 , 10, 1255-7	2.9	2
234	Adverse Effects of GLP-1 Receptor Agonists. <i>Review of Diabetic Studies</i> , 2014 , 11, 202-30	3.6	119
233	The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 787-812	5.5	42

232	No association between high-density lipoprotein levels and ventricular repolarization indexes in subjects with primary hypercholesterolemia. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2014 , 74, 53-8	2	3
231	Sodium-glucose co-transporter 2 inhibition in diabetes treatment: current evidence and future perspectives. <i>Current Pharmaceutical Design</i> , 2014 , 20, 3647-56	3.3	2
230	Recommendations for severe hypertriglyceridemia treatment, are there new strategies?. <i>Current Vascular Pharmacology</i> , 2014 , 12, 598-616	3.3	11
229	Rationale, design and baseline patient characteristics of the optimal type 2 diabetes management including benchmarking and standard treatment study in Greece. <i>World Journal of Diabetes</i> , 2014 , 5, 76-83	4.7	3
228	Colonoscopy preparation-induced disorders in renal function and electrolytes. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2014 , 5, 50-4	3	12
227	High density lipoproteins and type 2 diabetes: Emerging concepts in their relationship. <i>World Journal of Experimental Medicine</i> , 2014 , 4, 1-6	0.4	6
226	Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A _{II} in subjects with prediabetes. <i>Lipids</i> , 2013 , 48, 547-55	1.6	24
225	Autoimmune manifestations in patients with visceral leishmaniasis. <i>Journal of Microbiology, Immunology and Infection</i> , 2013 , 46, 302-5	8.5	20
224	Fenofibrate and the kidney: an overview. <i>European Journal of Clinical Investigation</i> , 2013 , 43, 522-31	4.6	38
223	Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. <i>Atherosclerosis</i> , 2013 , 231, 8-14	3.1	39
222	Metformin and cancer. <i>European Journal of Pharmacology</i> , 2013 , 705, 96-108	5.3	112
221	Current evidence and future perspectives of omega-3 polyunsaturated fatty acids for the prevention of cardiovascular disease. <i>European Journal of Pharmacology</i> , 2013 , 706, 1-3	5.3	8
220	The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of apoB/Lp-PLA _{II} . <i>Journal of Lipid Research</i> , 2013 , 54, 3394-402	6.3	6
219	Lipid-modulating treatments for mixed dyslipidemia increase HDL-associated phospholipase A ₂ activity with differential effects on HDL subfractions. <i>Lipids</i> , 2013 , 48, 957-65	1.6	2
218	Spurious electrolyte disorders: a diagnostic challenge for clinicians. <i>American Journal of Nephrology</i> , 2013 , 38, 50-7	4.6	66
217	Effect of simvastatin/ezetimibe 10/10 mg versus simvastatin 40 mg on serum vitamin D levels. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013 , 18, 229-33	2.6	15
216	Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose. <i>Metabolic Syndrome and Related Disorders</i> , 2013 , 11, 152-6	2.6	12
215	Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial. <i>European Journal of Clinical Investigation</i> , 2013 , 43, 698-707	4.6	11

214	Effects of statin monotherapy versus statin plus ezetimibe combination on serum uric acid levels. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013 , 18, 13-8	2.6	8
213	Effects of glucagon-like peptide-1 receptor agonists on renal function. <i>World Journal of Diabetes</i> , 2013 , 4, 190-201	4.7	47
212	Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?. <i>Review of Diabetic Studies</i> , 2013 , 10, 171-90	3.6	25
211	The effect of combining rosuvastatin with sartans of different peroxisome proliferator receptor- α activating capacity on plasma 8-isoprostane prostaglandin F _{2a} levels. <i>Archives of Medical Science</i> , 2013 , 9, 172-6	2.9	10
210	Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study. <i>Archives of Medical Science</i> , 2013 , 9, 788-95	2.9	19
209	Hyponatremia in patients with heart failure. <i>World Journal of Cardiology</i> , 2013 , 5, 317-28	2.1	43
208	Mitochondrial triglyceride transfer protein inhibition: new achievements in the treatment of dyslipidemias. <i>Current Pharmaceutical Design</i> , 2013 , 19, 3150-60	3.3	7
207	Pioglitazone and cancer: angel or demon?. <i>Current Pharmaceutical Design</i> , 2013 , 19, 4913-29	3.3	25
206	Combination therapies of DPP4 inhibitors and GLP1 analogues with insulin in type 2 diabetic patients: a systematic review. <i>Current Vascular Pharmacology</i> , 2013 , 11, 992-1000	3.3	13
205	Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia. <i>World Journal of Diabetes</i> , 2013 , 4, 365-71	4.7	11
204	Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2013 , 5, 470-8	3.4	111
203	High density lipoprotein and cardiovascular diseases. <i>World Journal of Cardiology</i> , 2013 , 5, 210-4	2.1	15
202	The relationship between adiponectin, an adiponectin gene polymorphism, and high-density lipoprotein particle size: from the Mima study. <i>Metabolism: Clinical and Experimental</i> , 2012 , 61, 17-21	12.7	16
201	A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. <i>Metabolism: Clinical and Experimental</i> , 2012 , 61, 906-21	12.7	83
200	New-onset extremely low levels of high-density lipoprotein cholesterol. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 593-5	4.9	6
199	Ezetimibe - a new approach in hypercholesterolemia management. <i>Pharmacological Reports</i> , 2012 , 64, 997-8	3.9	4
198	Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 1024-33	27.4	733
197	Effect of simvastatin or its combination with ezetimibe on Toll-like receptor expression and lipopolysaccharide - induced cytokine production in monocytes of hypercholesterolemic patients. <i>Atherosclerosis</i> , 2012 , 225, 381-7	3.1	37

196	Simvastatin interactions with other drugs. <i>Expert Opinion on Drug Safety</i> , 2012 , 11, 439-44	4.1	24
195	Hypomagnesemia in a department of internal medicine. <i>Magnesium Research</i> , 2012 , 25, 149-58	1.7	13
194	The relationship of vitamin D with non-traditional risk factors for cardiovascular disease in subjects with metabolic syndrome. <i>Archives of Medical Science</i> , 2012 , 8, 437-43	2.9	19
193	Nicotinic acid: clinical considerations. <i>Expert Opinion on Drug Safety</i> , 2012 , 11, 551-64	4.1	13
192	The changes in plasma retinol-binding protein 4 levels are associated with those of the apolipoprotein B-containing lipoproteins during dietary and drug treatment. <i>Angiology</i> , 2012 , 63, 67-75	2.1	11
191	Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece. <i>Angiology</i> , 2012 , 63, 184-93	2.1	13
190	Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. <i>Angiology</i> , 2012 , 63, 358-66	2.1	21
189	Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?. <i>Future Cardiology</i> , 2012 , 8, 813-7	1.3	2
188	Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipidemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2012 , 17, 427; author reply 428	2.6	2
187	Hypertriglyceridemia-induced acute pancreatitis: clinical considerations. <i>Clinical Lipidology</i> , 2012 , 7, 259-262		2
186	Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor- α activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A II . <i>Metabolic Syndrome and Related Disorders</i> , 2011 , 9, 217-23	2.6	3
185	Endocrine disorders: causes of hyponatremia not to neglect. <i>Annals of Medicine</i> , 2011 , 43, 179-87	1.5	38
184	Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: An Open-Label Randomized Study. <i>International Journal of Hypertension</i> , 2011 , 2011, 830434	2.4	4
183	Dyslipidemia associated with chronic kidney disease. <i>Open Cardiovascular Medicine Journal</i> , 2011 , 5, 41-80.7		78
182	Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. <i>Archives of Medical Science</i> , 2011 , 7, 796-805	2.9	51
181	Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. <i>Current Vascular Pharmacology</i> , 2011 , 9, 647-57	3.3	29
180	"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. <i>Current Vascular Pharmacology</i> , 2011 , 9, 531-2	3.3	91
179	Hypocholesterolemia. <i>Current Vascular Pharmacology</i> , 2011 , 9, 200-12	3.3	18

178	Hyponatremia in patients with infectious diseases. <i>Journal of Infection</i> , 2011 , 63, 327-35	18.9	47
177	Prediabetes: to treat or not to treat?. <i>European Journal of Pharmacology</i> , 2011 , 672, 9-19	5.3	22
176	Emerging options in the treatment of dyslipidemias: a bright future?. <i>Expert Opinion on Emerging Drugs</i> , 2011 , 16, 247-70	3.7	13
175	High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. <i>Lipids</i> , 2011 , 46, 521-8	1.6	20
174	Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress. <i>Lipids</i> , 2011 , 46, 341-8	1.6	24
173	Leptospirosis is associated with markedly increased triglycerides and small dense low-density lipoprotein and decreased high-density lipoprotein. <i>Lipids</i> , 2011 , 46, 953-60	1.6	21
172	The association between Type D personality and the metabolic syndrome: a cross-sectional study in a University-based outpatient lipid clinic. <i>BMC Research Notes</i> , 2011 , 4, 105	2.3	18
171	The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. <i>Current Medical Research and Opinion</i> , 2011 , 27, 685-92	2.5	24
170	The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2605-11	4	24
169	"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. <i>Current Vascular Pharmacology</i> , 2011 , 9, 533-7	3.3	138
168	Effect of Plant Polyphenols on Adipokine Secretion from Human SGBS Adipocytes. <i>Biochemistry Research International</i> , 2011 , 2011, 285618	2.4	26
167	Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 1945-58	4	21
166	Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. <i>Expert Review of Cardiovascular Therapy</i> , 2011 , 9, 355-66	2.5	16
165	An overview of lipid abnormalities in patients with inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2011 , 24, 181-187	2.2	57
164	What restricts the clinical use of nicotinic acid?. <i>Current Vascular Pharmacology</i> , 2011 , 9, 521-30	3.3	8
163	Role of ezetimibe in non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2011 , 3, 265-7	3.4	15
162	JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses. <i>World Journal of Cardiology</i> , 2011 , 3, 207-14	2.1	7
161	Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. <i>Vascular Health and Risk Management</i> , 2010 , 6, 525-39	4.4	36

160	Visfatin/PBEF and atherosclerosis-related diseases. <i>Current Vascular Pharmacology</i> , 2010 , 8, 12-28	3.3	51
159	Cardiovascular risk factors and estimated 10-year risk of fatal cardiovascular events using various equations in Greeks with metabolic syndrome. <i>Angiology</i> , 2010 , 61, 49-57	2.1	13
158	Centralized Pan-European survey on the undertreatment of hypercholesterolemia in patients using lipid lowering drugs--the CEPHEUS-Greece survey. <i>Angiology</i> , 2010 , 61, 465-74	2.1	16
157	Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study. <i>Angiology</i> , 2010 , 61, 365-71	2.1	7
156	Review article: effects of plant sterols and stanols beyond low-density lipoprotein cholesterol lowering. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010 , 15, 120-34	2.6	43
155	Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. <i>Current Medical Research and Opinion</i> , 2010 , 26, 445-54	2.5	57
154	Pharmacologically-induced metabolic acidosis: a review. <i>Drug Safety</i> , 2010 , 33, 371-91	5.1	31
153	Apolipoprotein B-to-A1 ratio as a predictor of acute ischemic nonembolic stroke in elderly subjects. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2010 , 19, 497-502	2.8	12
152	Plasma triglyceride levels and body mass index values are the most important determinants of prebeta-1 HDL concentrations in patients with various types of primary dyslipidemia. <i>Atherosclerosis</i> , 2010 , 208, 506-11	3.1	15
151	Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. <i>American Journal of Cardiovascular Drugs</i> , 2010 , 10, 11-28	4	65
150	Current role of statins in the treatment of essential hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 2635-50	4	13
149	Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia. <i>Current Vascular Pharmacology</i> , 2010 , 8, 820-30	3.3	22
148	Vitamin D and metabolic syndrome: is there a link?. <i>Current Pharmaceutical Design</i> , 2010 , 16, 3417-34	3.3	29
147	The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. <i>Lipids</i> , 2010 , 45, 445-50	1.6	22
146	Pleiotropic effects of ezetimibe: do they really exist?. <i>European Journal of Pharmacology</i> , 2010 , 633, 62-70	3.3	39
145	Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study. <i>Clinical Therapeutics</i> , 2010 , 32, 492-505	3.5	41
144	Do statins beneficially or adversely affect glucose homeostasis?. <i>Current Vascular Pharmacology</i> , 2010 , 8, 612-31	3.3	51
143	Combination drug treatment in obese diabetic patients. <i>World Journal of Diabetes</i> , 2010 , 1, 8-11	4.7	10

142	Combination drug treatment in patients with non-alcoholic fatty liver disease. <i>World Journal of Hepatology</i> , 2010 , 2, 139-42	3.4	18
141	Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2009 , 14, 5-13	2.6	27
140	A review of drug-induced hypernatraemia. <i>CKJ: Clinical Kidney Journal</i> , 2009 , 2, 339-46	4.5	7
139	Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2009 , 14, 274-82	2.6	6
138	How safe is the use of thiazolidinediones in clinical practice?. <i>Expert Opinion on Drug Safety</i> , 2009 , 8, 15-32	4.1	112
137	Statin pleiotropy against renal injury. <i>Journal of the Cardiometabolic Syndrome</i> , 2009 , 4, E4-9		30
136	Association between serum gamma-glutamyltransferase and acute ischemic nonembolic stroke in elderly subjects. <i>Archives of Medical Research</i> , 2009 , 40, 582-9	6.6	20
135	Evaluation of the proximal tubular function in individuals with primary renal hypouricemia: an NMR-based metabonomic study. <i>NMR in Biomedicine</i> , 2009 , 22, 1072-83	4.4	15
134	A review of drug-induced hypocalcemia. <i>Journal of Bone and Mineral Metabolism</i> , 2009 , 27, 635-42	2.9	75
133	Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. <i>Lipids</i> , 2009 , 44, 9-16	1.6	63
132	A patient with new-onset hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2009 , 3, 143-5	4.9	2
131	The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. <i>Diabetes, Obesity and Metabolism</i> , 2008 , 10, 476-83	6.7	52
130	Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. <i>European Journal of Pharmacology</i> , 2008 , 578, 249-52	5.3	25
129	Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. <i>European Journal of Pharmacology</i> , 2008 , 590, 327-32	5.3	21
128	A review of drug-induced hyponatremia. <i>American Journal of Kidney Diseases</i> , 2008 , 52, 144-53	7.4	297
127	Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. <i>Expert Opinion on Drug Safety</i> , 2008 , 7, 717-25	4.1	53
126	Orlistat-associated adverse effects and drug interactions: a critical review. <i>Drug Safety</i> , 2008 , 31, 53-65	5.1	217
125	Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome. <i>Journal of Clinical Lipidology</i> , 2008 , 2, 279-84	4.9	18

124	Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 1629-39	4	14
123	Causes and mechanisms of acid-base and electrolyte abnormalities in cancer patients. <i>European Journal of Internal Medicine</i> , 2008 , 19, 1-7	3.9	17
122	The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. <i>Current Medical Research and Opinion</i> , 2008 , 24, 1919-29	2.5	59
121	An overview of the extra-lipid effects of rosuvastatin. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2008 , 13, 157-74	2.6	63
120	The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 3151-8	4	31
119	Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 1829-37	4	16
118	Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 2741-50	4	12
117	Should a statin be prescribed to every patient with heart failure?. <i>Heart Failure Reviews</i> , 2008 , 13, 211-25		13
116	Gender-related and age-related urinalysis of healthy subjects by NMR-based metabonomics. <i>NMR in Biomedicine</i> , 2008 , 21, 195-207	4.4	114
115	Hypertriglyceridaemic waist phenotype criteria and prevalent metabolic triad in women. <i>Diabetes/Metabolism Research and Reviews</i> , 2008 , 24, 223-30	7.5	9
114	Clinical and laboratory characteristics of hypernatraemia in an internal medicine clinic. <i>Nephrology Dialysis Transplantation</i> , 2008 , 23, 136-43	4.3	36
113	Low HDL cholesterol, smoking and IL-13 R130Q polymorphism are associated with myocardial infarction in Greek Cypriot males. A pilot study. <i>Open Cardiovascular Medicine Journal</i> , 2008 , 2, 52-9	0.7	2
112	Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. <i>Current Medical Research and Opinion</i> , 2007 , 23, 1169-76	2.5	88
111	Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. <i>Journal of Endocrinological Investigation</i> , 2007 , 30, 323-6	5.2	97
110	Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin. <i>Archives of Medical Research</i> , 2007 , 38, 403-10	6.6	17
109	Plasma lipoproteins and triacylglycerol are predictors of small, dense LDL particles. <i>Lipids</i> , 2007 , 42, 403-9		33
108	Analysis of antihypertensive effects of statins. <i>Current Hypertension Reports</i> , 2007 , 9, 175-83	4.7	24
107	Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. <i>Nephrology Dialysis Transplantation</i> , 2007 , 22, 118-27	4.3	114

106	Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. <i>Scandinavian Journal of Gastroenterology</i> , 2007 , 42, 139-47	2.4	17
105	Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007 , 27, 2236-43	9.4	108
104	Dose-dependent effect of rosuvastatin treatment on urinary protein excretion. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2007 , 12, 292-7	2.6	21
103	Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. <i>Expert Opinion on Biological Therapy</i> , 2007 , 7, 53-72	5.4	81
102	Electrolyte disturbances in patients with hyponatremia. <i>Internal Medicine</i> , 2007 , 46, 685-90	1.1	26
101	Uric acid homeostasis in the evaluation of diuretic-induced hyponatremia. <i>Journal of Investigative Medicine</i> , 2007 , 55, 36-44	2.9	24
100	Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels. <i>Current Drug Targets</i> , 2007 , 8, 483-8	3	23
99	A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. <i>Clinical Therapeutics</i> , 2007 , 29, 1403-14	3.5	45
98	The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. <i>Lipids</i> , 2006 , 41, 647-54	1.6	66
97	The effect of cholesterol-lowering treatment on renal function. <i>American Journal of Kidney Diseases</i> , 2006 , 47, 561; author reply 562	7.4	10
96	Therapeutic approach in patients with dysnatraemias. <i>Nephrology Dialysis Transplantation</i> , 2006 , 21, 1564-9	4.9	82
95	Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006 , 11, 1-15	2.6	30
94	Autoantibody titers against OxLDL are correlated with Achilles tendon thickness in patients with familial hypercholesterolemia. <i>Journal of Lipid Research</i> , 2006 , 47, 2208-14	6.3	27
93	Effect of barnidipine on blood pressure and serum metabolic parameters in patients with essential hypertension: a pilot study. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006 , 11, 256-61	2.6	20
92	LDL cholesterol estimation in patients with the metabolic syndrome. <i>Lipids in Health and Disease</i> , 2006 , 5, 8	4.4	24
91	Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. <i>Current Medical Research and Opinion</i> , 2006 , 22, 873-83	2.5	191
90	The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006 , 11, 211-21	2.6	31
89	Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals. <i>Atherosclerosis</i> , 2006 , 187, 170-6	3.1	34

88	Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATORvastatin and ROSuvastatin (the ATOROS study). <i>Current Medical Research and Opinion</i> , 2006 , 22, 1123-31	2.5	55
87	Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. <i>Metabolism: Clinical and Experimental</i> , 2006 , 55, 885-91	12.7	64
86	Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?. <i>Metabolism: Clinical and Experimental</i> , 2006 , 55, 1293-301	12.7	208
85	Sevelamer Hydrochloride versus Aluminum Hydroxide: Effect on Serum Phosphorus and Lipids in CAPD Patients. <i>Peritoneal Dialysis International</i> , 2006 , 26, 320-321	2.8	26
84	Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 1337-43	2.9	22
83	Effect of apolipoprotein E polymorphism on serum uric acid levels in healthy subjects. <i>Journal of Investigative Medicine</i> , 2005 , 53, 116-22	2.9	12
82	Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. <i>Current Medical Research and Opinion</i> , 2005 , 21, 1997-2006	2.5	90
81	New-onset diabetes after transplantation. <i>Lancet, The</i> , 2005 , 365, 1766	40	3
80	A review of the lipid-related effects of fluvastatin. <i>Current Medical Research and Opinion</i> , 2005 , 21, 231-44	4.5	34
79	Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals. <i>International Journal of Cardiology</i> , 2005 , 99, 269-75	3.2	54
78	Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2005 , 72, 203-9	2.8	42
77	Apolipoprotein E polymorphism and the risk of acute nephropathy after cardiac surgery. <i>Annals of Thoracic Surgery</i> , 2005 , 80, 382-3; author reply 383	2.7	
76	The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. <i>Current Medical Research and Opinion</i> , 2005 , 21, 1157-9	3.5	138
75	A review of the metabolic effects of sibutramine. <i>Current Medical Research and Opinion</i> , 2005 , 21, 457-68	2.5	85
74	Alterations in electrolyte equilibrium in patients with acute leukemia. <i>European Journal of Haematology</i> , 2005 , 75, 449-60	3.8	37
73	Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. <i>Clinical Chemistry</i> , 2005 , 51, 2264-73	5.5	146
72	Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. <i>Stroke</i> , 2005 , 36, 1372-6	6.7	94
71	Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering?. <i>Angiology</i> , 2005 , 56, 585-92	2.1	16

70	Fenofibrate: metabolic and pleiotropic effects. <i>Current Vascular Pharmacology</i> , 2005 , 3, 87-98	3.3	53
69	Evaluation of methods for the measurement of low-density lipoprotein cholesterol. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2005 , 10, 45-54	2.6	80
68	Diagnosis of the metabolic syndrome: which definition should we use?. <i>Hellenic Journal of Cardiology</i> , 2005 , 46, 258-62	2.1	
67	Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. <i>Hellenic Journal of Cardiology</i> , 2005 , 46, 380-6	2.1	17
66	Alterations of Paraoxonase and Platelet-Activating Factor Acetylhydrolase Activities in Patients on Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2004 , 24, 580-589	2.8	19
65	Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. <i>Current Medical Research and Opinion</i> , 2004 , 20, 627-37	2.5	62
64	Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. <i>Current Medical Research and Opinion</i> , 2004 , 20, 1691-1701	2.5	72
63	Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2004 , 9, 91-5	2.6	27
62	Serum lipid profile in patients with severe leptospirosis. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 1328-9; author reply 1329-30	4.3	10
61	Influence of apolipoprotein E polymorphisms on serum creatinine levels and predicted glomerular filtration rate in healthy subjects. <i>Nephrology Dialysis Transplantation</i> , 2004 , 19, 2006-12	4.3	21
60	The impact of serum uric acid on cardiovascular outcomes in the LIFE study. <i>Kidney International</i> , 2004 , 66, 1714-5	9.9	24
59	Apolipoprotein E and renal disease. <i>American Journal of Kidney Diseases</i> , 2004 , 43, 223-33	7.4	88
58	Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. <i>American Journal of Kidney Diseases</i> , 2004 , 43, 589-99	7.4	188
57	The influence of serum apolipoprotein E concentration and polymorphism on serum lipid parameters in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2004 , 44, 300-8	7.4	22
56	Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. <i>American Heart Journal</i> , 2004 , 148, 635-40	4.9	101
55	Metabolic Syndrome: Clinical Features Leading to Therapeutic Strategies. <i>Vascular Disease Prevention</i> , 2004 , 1, 243-253		14
54	Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. <i>Journal of Clinical Pharmacology</i> , 2003 , 43, 825-30	2.9	45
53	The PON1 M55L gene polymorphism is associated with reduced HDL-associated PAF-AH activity. <i>Journal of Lipid Research</i> , 2003 , 44, 1919-26	6.3	19

52	Effect of atorvastatin on the concentration, relative distribution, and chemical composition of lipoprotein subfractions in patients with dyslipidemias of type IIA and IIB. <i>Journal of Cardiovascular Pharmacology</i> , 2003 , 42, 304-10	3.1	15
51	Could apolipoprotein E polymorphisms be hidden behind the relation between bone mineral density and atherosclerosis in hemodialysis patients?. <i>Osteoporosis International</i> , 2003 , 14, 957	5.3	4
50	Hypouricemia in individuals admitted to an inpatient hospital-based facility. <i>American Journal of Kidney Diseases</i> , 2003 , 41, 1225-32	7.4	23
49	Lipoprotein (a) levels and apolipoprotein (a) isoform size in patients with subclinical hypothyroidism: effect of treatment with levothyroxine. <i>Thyroid</i> , 2003 , 13, 365-9	6.2	35
48	Fibrates and C-reactive protein. <i>Clinica Chimica Acta</i> , 2003 , 328, 197	6.2	1
47	Early vascular benefits of statin therapy. <i>Current Medical Research and Opinion</i> , 2003 , 19, 540-56	2.5	132
46	Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. <i>Journal of Lipid Research</i> , 2003 , 44, 927-34	6.3	94
45	Statins and renal function in patients with diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2003 , 19, 615-7	2.5	57
44	Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002 , 22, 306-11	9.4	131
43	Hypokalaemia in alcoholic patients. <i>Drug and Alcohol Review</i> , 2002 , 21, 73-6	3.2	33
42	Effects of fibrates on serum metabolic parameters. <i>Current Medical Research and Opinion</i> , 2002 , 18, 269-76	2.6	151
41	Statins and renal function. <i>Angiology</i> , 2002 , 53, 493-502	2.1	83
40	Effect of ciprofibrate on C-reactive protein and fibrinogen levels. <i>Angiology</i> , 2002 , 53, 273-7	2.1	45
39	Hypomagnesemia and concurrent acid-base and electrolyte abnormalities in patients with congestive heart failure. <i>European Journal of Heart Failure</i> , 2002 , 4, 167-73	12.3	53
38	The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide. <i>Current Medical Research and Opinion</i> , 2002 , 18, 59-63	2.5	21
37	The hyponatremic patient: a systematic approach to laboratory diagnosis. <i>Cmaj</i> , 2002 , 166, 1056-62	3.5	30
36	Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. <i>Journal of Lipid Research</i> , 2002 , 43, 256-263	6.3	101
35	Rhabdomyolysis-related Renal Tubular Damage Studied by Proton Nuclear Magnetic Resonance Spectroscopy of Urine. <i>Clinical Chemistry</i> , 2002 , 48, 1106-1109	5.5	29

34	Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. <i>Journal of Lipid Research</i> , 2002 , 43, 256-63	6.3	90
33	Severe hypocholesterolemia with reduced serum lipoprotein(a) in a patient with visceral leishmaniasis. <i>Annals of Clinical and Laboratory Science</i> , 2002 , 32, 305-8	0.9	20
32	A tumor lysis-like syndrome during therapy of visceral leishmaniasis. <i>Annals of Clinical and Laboratory Science</i> , 2002 , 32, 419-21	0.9	6
31	Serum uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment. <i>Fundamental and Clinical Pharmacology</i> , 2001 , 15, 401-3	3.1	8
30	Renal abnormalities in sickle-cell beta-thalassemia. <i>American Journal of Hematology</i> , 2001 , 66, 68-9	7.1	1
29	Reversible tubular dysfunction that mimicked Fanconi's syndrome in a patient with anorexia nervosa. <i>International Journal of Eating Disorders</i> , 2001 , 30, 227-30	6.3	30
28	Characterization and geographic distribution of the low density lipoprotein receptor (LDLR) gene mutations in northwestern Greece. <i>Human Mutation</i> , 2001 , 17, 432-3	4.7	22
27	Partially reversible renal tubular damage in patients with obstructive jaundice. <i>Hepatology</i> , 2001 , 33, 1365-9	11.2	52
26	The Treatment of Coronary Heart Disease: An Update. <i>Current Medical Research and Opinion</i> , 2001 , 17, 18-26	2.5	27
25	Serum lipoprotein(a) concentrations and apolipoprotein(a) isoforms: association with the severity of clinical presentation in patients with coronary heart disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2001 , 8, 311-7		9
24	Effect of atorvastatin on serum creatinine levels. <i>Current Medical Research and Opinion</i> , 2001 , 17, 230-1	2.5	22
23	Effect of atorvastatin on serum uric acid levels. <i>Atherosclerosis</i> , 2001 , 158, 255	3.1	20
22	Segregation of a novel LDLR gene mutation (I430T) with familial hypercholesterolaemia in a Greek pedigree. <i>Human Mutation</i> , 2000 , 16, 277	4.7	6
21	Estimation of LDL cholesterol based on the Friedewald formula and on apo B levels. <i>Clinical Biochemistry</i> , 2000 , 33, 549-55	3.5	70
20	Hypokalemia, hypophosphatemia and hypouricemia due to proximal renal tubular dysfunction in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2000 , 64, 277-8	3.8	8
19	Aminoglycoside-induced metabolic abnormalities. <i>Annals of Clinical Biochemistry</i> , 2000 , 37 (Pt 4), 543-4	2.2	4
18	Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil. <i>American Journal of Medicine</i> , 2000 , 109, 261-2	2.4	51
17	Treatment of Dyslipidaemias in Patients with Established Vascular Disease: A Revival of the Fibrates. <i>Current Medical Research and Opinion</i> , 2000 , 16, 21-32	2.5	25

16	Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy. <i>Cardiovascular Research</i> , 1999 , 43, 183-91	9.9	16
15	Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1999 , 6, 113-6		37
14	The incidence of thyroid function abnormalities in patients attending an outpatient lipid clinic. <i>Thyroid</i> , 1999 , 9, 365-8	6.2	39
13	Severe life-threatening hyperphosphatemia associated with tumor lysis in a patient with acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 1999 , 60, 252	7.1	3
12	Acid-base and electrolyte abnormalities in patients with acute leukemia. <i>American Journal of Hematology</i> , 1999 , 62, 201-7	7.1	36
11	Hypomagnesemia in alcoholic patients. <i>Alcoholism: Clinical and Experimental Research</i> , 1998 , 22, 134	3.7	14
10	Atypical presentation of post-partum visceral Leishmaniasis. <i>American Journal of Hematology</i> , 1998 , 57, 89-90	7.1	
9	Retrosternal abscess: a prominent manifestation of infection due to Staphylococcus aureus. <i>Clinical Infectious Diseases</i> , 1998 , 26, 1462-4	11.6	1
8	Lipoprotein (a) concentrations in patients with various dyslipidaemias. <i>Annals of Medicine</i> , 1997 , 29, 305-9	5	
7	Electrolyte abnormalities in elderly patients admitted to a general medical ward. <i>Geriatric Nephrology and Urology</i> , 1997 , 7, 73-9		6
6	Concurrence of giant cell arteritis in a patient with de quervain's thyroiditis. <i>Clinical Endocrinology</i> , 1997 , 47, 760-1	3.4	1
5	Successful treatment of hyponatremia with angiotensin-converting enzyme inhibitors in patients with congestive heart failure. <i>Cardiology</i> , 1995 , 86, 477-80	1.6	12
4	Hyperkalemic hyperchloremic metabolic acidosis in a patient with sickle cell beta-thalassemia. <i>American Journal of Hematology</i> , 1995 , 50, 151-2	7.1	
3	The value of alpha-amylase and isoamylase determination in chronic renal failure patients. <i>International Journal of Gastrointestinal Cancer</i> , 1994 , 15, 105-11		8
2	Lipid abnormalities in chronic uremic patients. Response to treatment with gemfibrozil. <i>Scandinavian Journal of Urology and Nephrology</i> , 1993 , 27, 101-8		12
1	Aminoglycoside-Induced Metabolic Abnormalities		2